Archive · 14 Sep 2026
Semaglutide Helps Children With Obesity, But Raises Caution
Researchers tested a medicine called semaglutide in children aged 6 to under 12 who had obesity.
The medicine was given once each week for 68 weeks.
About four out of every ten children who received it were no longer above the obesity threshold.
None of the children given a placebo reached that result.
Both groups also followed a lower-calorie diet and became more physically active.
This means the medicine appeared to add benefits beyond lifestyle changes alone.
Doctors say it could help some children with severe obesity avoid future health problems.
However, researchers do not yet know what happens after many years of treatment.
The medicine should support healthy family habits rather than replace them.
A Phase III trial found that 40.4% of treated children moved below the obesity threshold after 68 weeks.
None of the children receiving placebo moved below the obesity threshold.
The STEP Young trial included 165 children aged 6 to under 12, alongside diet and physical-activity changes.
The findings may be especially meaningful for children with severe obesity and related metabolic risks.
Experts stress that long-term safety, nutrition, cost, access and family habits require continued attention.
- Who
- The STEP Young trial involved 165 children aged 6 to under 12 with obesity, and was conducted by Novo Nordisk.
- What
- A Phase III trial tested once-weekly semaglutide alongside diet and increased physical activity.
- When
- The treatment and follow-up lasted 68 weeks.
- Why
- The trial assessed whether semaglutide could reduce body mass index and help children move below the obesity threshold.
Potential Benefits
Reasons for Caution
Medical value
Potential Benefits
Semaglutide could provide meaningful additional weight reduction for carefully selected children with severe obesity and may help reduce future risks such as Type 2 diabetes, fatty liver disease and hypertension.
Reasons for Caution
Treating children so young raises questions about whether medication could medicalise obesity without adequately addressing family, dietary and environmental factors.
Safety and development
Potential Benefits
The available 68-week trial data showed no major adverse signals involving growth or pubertal development.
Reasons for Caution
The study was relatively short and cannot establish the effects of decades of exposure, so long-term monitoring remains necessary.
Practical use
Potential Benefits
Medication may help interrupt worsening obesity and improve physical functioning and some psychological burdens associated with severe obesity.
Reasons for Caution
Reduced appetite could make it harder for growing children to obtain enough protein and micronutrients, while high costs and limited availability may restrict access in India.
- Trial
- STEP Young, a Phase III clinical trial
- Participants
- 165 children aged 6 to under 12
- Treatment period
- 68 weeks
- Semaglutide result
- 40.4% moved below the obesity threshold
- Placebo result
- None moved below the obesity threshold
- Additional measures
- Both groups followed a reduced-calorie diet and increased physical activity
- Main unresolved issue
- The trial period cannot answer questions about decades of exposure